Bio-Techne Announces Opening Of New Canadian Facility
Bio-Techne Corporation (NASDAQ:TECH) has opened a new office in Toronto, Canada, housing approximately 40 employees. This facility aims to support the Canadian life sciences industry and will service academic and biopharma clients with Bio-Techne's life science tools and diagnostic reagents. The Toronto office will also manufacture and distribute cartridges for the Protein Simple branded iCE and Maurice systems, enhancing the company’s production capacity. Designed for energy efficiency, it meets ISO 9001 standards to ensure high-quality operations.
- Opening a new facility in Toronto enhances support for Canadian customers.
- The Toronto office will manufacture cartridges, increasing production capacity.
- The facility is designed to be environmentally friendly with energy-efficient features.
- ISO 9001 compliance indicates high-quality standards in operations.
- None.
MINNEAPOLIS, Oct. 1, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Canadian office located in Toronto. This new office will be the workplace for approximately 40 Bio-Techne employees and reflects the Company's commitment to supporting the Canadian life sciences industry as well as expectations for continued growth in this geography.
The Toronto office is responsible for servicing Bio-Techne's growing number of Canadian-based academic and biopharma customers with the Company's full portfolio of life science tools and diagnostic reagents. Additionally, Toronto is the primary facility responsible for manufacturing and distributing cartridges used on its Protein Simple branded iCE and Maurice systems. The additional manufacturing capacity at the new site positions Bio-Techne to meet increasing utilization and sales of both of these systems.
Bio-Techne's new Canadian office was designed to be environmentally friendly, including LED lighting and the use of motion sensors for energy conservation. The facility is also ISO 9001 compliant and certified, meeting the high-quality standards and third-party audit requirements to receive this designation.
"Bio-Techne is pleased to make this additional investment in Canada," said Dave Eansor, President Protein Sciences Segment. "This new facility positions Bio-Techne for additional growth in this geography as we continue to support our Canadian academic and biopharmaceutical customers."
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-opening-of-new-canadian-facility-301138818.html
SOURCE Bio-Techne Corporation
